Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
Impact of peripheral mutations on the access channels of human cytochrome P450 1A2.
Ying B et al.
Journal of Biomolecular Structure & Dynamics, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
Lewis BC et al.
Pharmacogenetics and Genomics, 2016
Cytochrome P450 expression system for high-throughput real-time detection of genotoxicity: Application to the study of human CYP1A2 variants.
Palma BB et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis, 2016
Differences in Methadone Metabolism by CYP2B6 Variants.
Gadel S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015
Functional characterization of 20 allelic variants of CYP1A2.
Ito M et al.
Drug Metabolism and Pharmacokinetics, 2015
Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A2*8, *15, and *16 (R456H, P42R, and R377Q).
Lim YR et al.
Biomolecules & Therapeutics, 2015
Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae.
Fasullo M et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis, 2014
Functional characterization of eight human CYP1A2 variants: the role of cytochrome b5.
Palma BB et al.
Pharmacogenetics and Genomics, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression.
Palma BB et al.
The Pharmacogenomics Journal, 2010
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF et al.
Drug Metabolism Reviews, 2010
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.
Klein K et al.
Frontiers in Pharmacology, 2010
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
Zhou SF et al.
The Aaps Journal, 2009
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.
Tiwari AK et al.
The Pharmacogenomics Journal, 2007
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T et al.
American Family Physician, 2007
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R et al.
European Journal of Clinical Pharmacology, 2007
Functional analysis of three CYP1A2 variants found in a Japanese population.
Saito Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK et al.
The Pharmacogenomics Journal, 2005
Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer.
Tsukino H et al.
Journal of Cancer Research and Clinical Oncology, 2004
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
Sachse C et al.
British Journal of Clinical Pharmacology, 2003
Genetic polymorphism of human cytochrome p450 involved in drug metabolism.
Nagata K et al.
Drug Metabolism and Pharmacokinetics, 2002
Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population.
Chevalier D et al.
Human Mutation, 2001